Jeffery MD - Bio Path Consultant
| BPTHDelisted Stock | USD 0.19 0.01 5.00% |
Insider
Jeffery MD is Consultant of Bio Path Holdings
| Phone | 832 742 1357 |
| Web | https://www.biopathholdings.com |
Bio Path Management Efficiency
The company has return on total asset (ROA) of (1.9409) % which means that it has lost $1.9409 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (11.5974) %, meaning that it created substantial loss on money invested by shareholders. Bio Path's management efficiency ratios could be used to measure how well Bio Path manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| MBA CMA | Pulmatrix | 70 | |
| Torsten Hombeck | Akari Therapeutics PLC | 55 | |
| Michael MSBA | NextCure | 64 | |
| John MBA | Achieve Life Sciences | 47 | |
| Louis Ploth | Moleculin Biotech | 70 | |
| MBA MD | Moleculin Biotech | N/A | |
| Craig Lewis | Benitec Biopharma Ltd | N/A | |
| Adriana MBA | Crinetics Pharmaceuticals | N/A | |
| Timothy Mayer | NextCure | 60 | |
| Jacqueline Northcut | Moleculin Biotech | 62 | |
| Jerry Wan | Achieve Life Sciences | 43 | |
| Aidan Curran | Pulmatrix | N/A | |
| Margaret MD | Pulmatrix | 67 | |
| Eduardo Marbn | Capricor Therapeutics | N/A | |
| Chris MBA | Crinetics Pharmaceuticals | N/A | |
| Catherine Kelleher | Capricor Therapeutics | N/A | |
| Linda Marbn | Capricor Therapeutics | 62 | |
| Xavier Avat | Capricor Therapeutics | N/A | |
| FACP MD | Moleculin Biotech | 70 | |
| Ray MD | Akari Therapeutics PLC | 79 | |
| Donald Picker | Moleculin Biotech | 79 | |
Management Performance
| Return On Equity | -11.6 | ||||
| Return On Asset | -1.94 |
Bio Path Holdings Leadership Team
Elected by the shareholders, the Bio Path's board of directors comprises two types of representatives: Bio Path inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bio. The board's role is to monitor Bio Path's management team and ensure that shareholders' interests are well served. Bio Path's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bio Path's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alan MacKenzie, Consultant | ||
| Thomas Walker, Consultant | ||
| MBA Ashizawa, Development Research | ||
| Michael MBA, VP Operations | ||
| Peter MBA, Chairman, CoFounder | ||
| Jeffery MD, Consultant | ||
| Victoria Rac, Regulatory Consultant | ||
| Anthony Price, Accounting Finance | ||
| Douglas Morris, Co-Founder and Director | ||
| MBA MBA, Development Research | ||
| Anthony MBA, Accounting Finance |
Bio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Bio Path a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -11.6 | ||||
| Return On Asset | -1.94 | ||||
| Current Valuation | 531.06 K | ||||
| Shares Outstanding | 5.77 M | ||||
| Shares Owned By Institutions | 7.41 % | ||||
| Number Of Shares Shorted | 79.35 K | ||||
| Price To Earning | (6.21) X | ||||
| Price To Book | 2.33 X | ||||
| EBITDA | (15.76 M) | ||||
| Net Income | (16.08 M) |
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Path Holdings. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Other Consideration for investing in Bio OTC Stock
If you are still planning to invest in Bio Path Holdings check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bio Path's history and understand the potential risks before investing.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |